Posted by Michael Wonder on 06 Dec 2021
Chiesi Global Rare Diseases announces updated U.S. Prescribing Information for Ferriprox (deferiprone)
3 December 2021 - Chiesi Global Rare Diseases announced today that the Ferriprox (deferiprone) Prescribing Information in the U.S. has been updated in the treatment of transfusional iron overload in patients with thalassemia syndromes, sickle cell disease or other anemias.
The updated Prescribing Information includes changes to the regular monitoring of the absolute neutrophil count in patients while on therapy.
